Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators..

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

PMID:
27913695
2.

Genetic and Clinical Predictors of Deep Brain Stimulation in Young-Onset Parkinson's Disease.

Pal GD, Hall D, Ouyang B, Phelps J, Alcalay R, Pauciulo MW, Nichols WC, Clark L, Mejia-Santana H, Blasucci L, Goetz CG, Comella C, Colcher A, Gan-Or Z, Rouleau GA, Marder K; Consortium on Risk for Early Onset Parkinson's Disease (CORE-PD) Investigators..

Mov Disord Clin Pract. 2016 Sep-Oct;3(5):465-471. Epub 2016 Jan 18.

3.

Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD).

Parkinson Study Group..

Mov Disord. 2013 Nov;28(13):1823-31. doi: 10.1002/mds.25639. Epub 2013 Sep 30.

PMID:
24123224
5.

Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts.

Marras C, McDermott MP, Marek K, Rochon P, Naglie G, Tanner CM, Rudolph A, Shoulson I, Lang AE; Parkinson Study Group DATATOP and PRECEPT investigators..

Mov Disord. 2011 Mar;26(4):608-13. doi: 10.1002/mds.23581. Epub 2011 Feb 1.

PMID:
21287602
6.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators..

Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828.

PMID:
19908310
7.

Testing objective measures of motor impairment in early Parkinson's disease: Feasibility study of an at-home testing device.

Goetz CG, Stebbins GT, Wolff D, DeLeeuw W, Bronte-Stewart H, Elble R, Hallett M, Nutt J, Ramig L, Sanger T, Wu AD, Kraus PH, Blasucci LM, Shamim EA, Sethi KD, Spielman J, Kubota K, Grove AS, Dishman E, Taylor CB.

Mov Disord. 2009 Mar 15;24(4):551-6. doi: 10.1002/mds.22379.

8.

Fatigue in levodopa-naive subjects with Parkinson disease.

Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson Study Group ELLDOPA Investigators..

Neurology. 2008 Aug 12;71(7):481-5. doi: 10.1212/01.wnl.0000324862.29733.69.

9.

Evaluating Parkinson's disease patients at home: utility of self-videotaping for objective motor, dyskinesia, and ON-OFF assessments.

Goetz CG, Leurgans S, Hinson VK, Blasucci LM, Zimmerman J, Fan W, Nguyen T, Hsu A.

Mov Disord. 2008 Jul 30;23(10):1479-82. doi: 10.1002/mds.22127.

PMID:
18512751
10.

Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome.

Pappert EJ, Goetz CG, Louis ED, Blasucci L, Leurgans S.

Neurology. 2003 Oct 14;61(7):936-40.

PMID:
14557563
11.

Impact of placebo assignment in clinical trials of Parkinson's disease.

Goetz CG, Janko K, Blasucci L, Jaglin JA.

Mov Disord. 2003 Oct;18(10):1146-9.

PMID:
14534918
12.

Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics.

Kompoliti K, Adler CH, Raman R, Pincus JH, Leibowitz MT, Ferry JJ, Blasucci L, Caviness JN, Leurgans S, Chase WM, Yones LC, Tan E, Carvey P, Goetz CG.

Neurology. 2002 May 14;58(9):1418-22.

PMID:
12011296
13.

A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease.

Shoulson I, Penney J, McDermott M, Schwid S, Kayson E, Chase T, Fahn S, Greenamyre JT, Lang A, Siderowf A, Pearson N, Harrison M, Rost E, Colcher A, Lloyd M, Matthews M, Pahwa R, McGuire D, Lew MF, Schuman S, Marek K, Broshjeit S, Factor S, Brown D, Feigin A, Mazurkiewicz J, Ford B, Jennings D, Dilllon S, Comella C, Blasucci L, Janko K, Shulman L, Wiener W, Bateman-Rodriguez D, Carrion A, Suchowersky O, Lafontaine AL, Pantella C, Siemers E, Belden J, Davies R, Lannon M, Grimes D, Gray P, Martin W, Kennedy L, Adler C, Newman S, Hammerstad J, Stone C, Lewitt P, Bardram K, Mistura K, Miyasaki J, Johnston L, Cha JH, Tennis M, Panniset M, Hall J, Tetrud J, Friedlander J, Hauser R, Gauger L, Rodnitzky R, Deleo A, Dobson J, Seeberger L, Dingmann C, Tarsy D, Ryan P, Elmer L, Ruzicka D, Stacy M, Brewer M, Locke B, Baker D, Casaceli C, Day D, Florack M, Hodgeman K, Laroia N, Nobel R, Orme C, Rexo L, Rothenburgh K, Sulimowicz K, Watts A, Wratni E, Tariot P, Cox C, Leventhal C, Alderfer V, Craun AM, Frey J, McCree L, McDermott J, Cooper J, Holdich T, Read B; Parkinson Study Group..

Neurology. 2001 Feb 27;56(4):455-62.

PMID:
11222787
14.

Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study.

Goetz CG, Burke PF, Leurgans S, Berry-Kravis E, Blasucci LM, Raman R, Zhou L.

Arch Neurol. 2001 Feb;58(2):209-13.

PMID:
11176958
15.

Acute orthostatic hypotension when starting dopamine agonists in Parkinson's disease.

Kujawa K, Leurgans S, Raman R, Blasucci L, Goetz CG.

Arch Neurol. 2000 Oct;57(10):1461-3.

PMID:
11030798
16.

Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.

Goetz CG, Blasucci LM, Leurgans S, Pappert EJ.

Neurology. 2000 Sep 26;55(6):789-94.

PMID:
10993997
17.

Differential progression of motor impairment in levodopa-treated Parkinson's disease.

Goetz CG, Stebbins GT, Blasucci LM.

Mov Disord. 2000 May;15(3):479-84.

PMID:
10830412
18.

Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?

Goetz CG, Blasucci L, Stebbins GT.

Neurology. 1999 Apr 12;52(6):1227-9.

PMID:
10214748
19.

Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations.

Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, Carvey PM.

Neurology. 1998 Feb;50(2):515-7.

PMID:
9484386
20.

Efficacy of a patient-training videotape on motor fluctuations for on-off diaries in Parkinson's disease.

Goetz CG, Stebbins GT, Blasucci LM, Grobman MS.

Mov Disord. 1997 Nov;12(6):1039-41.

PMID:
9399233

Supplemental Content

Loading ...
Support Center